The unbiased two-step cluster analysis in 185 patients with myositis-associated ILD who received initial triple-combo therapy identified 6 clusters, which were categorized by the following 7 explanatory variables: age at disease onset, CADM, CRP, KL-6, requirement of supplemental oxygen, anti-ARS antibody, and anti-MDA5 antibody (Figure 1). The gene discussed is IFIH1; the disease is myositis disease.